These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31778624)

  • 1. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
    Berkemeier F; Whaley C; Robinson JC
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
    Kleining K; Laufenberg J; Thrun P; Ehlert D; Wasem J; Bartol A
    Health Econ Policy Law; 2024 Apr; 19(2):216-233. PubMed ID: 37577932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
    DiStefano MJ; Levy JF; Odouard IC; Anderson GF
    Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market Power: Price Variation Among Commercial Insurers For Hospital Services.
    Bai G; Anderson GF
    Health Aff (Millwood); 2018 Oct; 37(10):1615-1622. PubMed ID: 30273037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007-20.
    Mallatt J; Dunn A; Fernando L
    Health Aff (Millwood); 2024 Sep; 43(9):1284-1289. PubMed ID: 39226496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician Reimbursement in Medicare Advantage Compared With Traditional Medicare and Commercial Health Insurance.
    Trish E; Ginsburg P; Gascue L; Joyce G
    JAMA Intern Med; 2017 Sep; 177(9):1287-1295. PubMed ID: 28692718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
    Sullivan SD
    Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Price-Quality Mismatch: Are Negotiated Prices for Total Joint Arthroplasty Associated With Hospital Quality in a Large California Health System?
    Zhuang T; Shapiro LM; Baker LC; Kamal RN
    Clin Orthop Relat Res; 2023 Jun; 481(6):1061-1068. PubMed ID: 36729581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program.
    Sullivan SD; Wouters OJ; Cousin EM; Kirihennedige AS; Hernandez I
    Value Health; 2024 Oct; 27(10):1348-1357. PubMed ID: 39154910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.